Weight-Based Unfractionated Heparin After Thrombolysis for STEMI
For STEMI patients receiving thrombolytic therapy, initiate unfractionated heparin with a 60 U/kg IV bolus (maximum 4000 U) followed by 12 U/kg/hour continuous infusion (maximum 1000 U/hour), targeting an aPTT of 1.5-2.0 times control (approximately 50-70 seconds) for at least 48 hours. 1
Dosing Protocol
The 2013 ACC/AHA STEMI guidelines provide Class I, Level A recommendations for weight-based UFH dosing as adjunctive therapy with fibrinolysis 1:
- Initial bolus: 60 U/kg IV (maximum 4000 U)
- Continuous infusion: 12 U/kg/hour (maximum 1000 U/hour)
- Target aPTT: 1.5-2.0 times control (50-70 seconds)
- Duration: Minimum 48 hours, preferably until hospital discharge (up to 8 days) or revascularization
The FDA labeling for heparin confirms these weight-based regimens for therapeutic anticoagulation, emphasizing the need for dose adjustment based on coagulation testing 2.
Monitoring Strategy
Check aPTT at baseline, then approximately every 4 hours after initiating the infusion until stable, then at appropriate intervals thereafter 2. The dosing is adequate when aPTT reaches 1.5-2.0 times the control value 1.
Additionally, monitor:
- Platelet counts periodically (to detect heparin-induced thrombocytopenia)
- Hematocrit
- Occult blood in stool
- Signs of bleeding
Critical Dosing Considerations
Weight Caps Are Essential
The maximum bolus of 4000 U and maximum infusion rate of 1000 U/hour exist to prevent overdosing in heavier patients 1. Recent evidence from the 2024 ESC consensus statement highlights that conventional weight-based nomograms can lead to overdosing in patients with Class ≥2 obesity (BMI ≥35), potentially increasing bleeding risk 3. For patients >120 kg, consider using ideal body weight rather than actual body weight for dosing calculations.
Timing Matters
While the guidelines recommend UFH as adjunctive therapy with fibrinolysis, recent data suggests earlier administration may improve outcomes. The 2026 HEPARIN-STEMI trial demonstrated that prehospital UFH (70-100 U/kg bolus) increased infarct-related artery patency by 16% absolute risk reduction without increased bleeding 4. However, the established guideline-recommended approach remains to initiate UFH concurrently with or immediately after thrombolytic administration 1.
Common Pitfalls to Avoid
- Failing to cap the dose: Always apply the 4000 U bolus and 1000 U/hour infusion maximums
- Inadequate aPTT monitoring: Check every 4 hours initially—subtherapeutic anticoagulation increases risk of reocclusion
- Using actual body weight in obese patients: Consider ideal body weight for patients >120 kg to avoid overdosing 3
- Premature discontinuation: Continue for minimum 48 hours, preferably longer unless contraindicated
- Mixing up vial concentrations: Confirm correct heparin concentration before administration to prevent fatal dosing errors 2
Alternative: Low-Molecular-Weight Heparin
The guidelines also provide Class I, Level A recommendations for enoxaparin as an alternative 1:
- Age <75 years: 30 mg IV bolus, then 1 mg/kg subcutaneously every 12 hours (maximum 100 mg for first 2 doses)
- Age ≥75 years: No bolus, 0.75 mg/kg subcutaneously every 12 hours (maximum 75 mg for first 2 doses)
- Renal impairment (CrCl <30 mL/min): 1 mg/kg subcutaneously every 24 hours
Meta-analyses demonstrate that LMWH reduces reinfarction by approximately 25% and mortality by 10% compared to placebo, and reduces reinfarction by 45% when directly compared to UFH 5. However, LMWH increases major bleeding compared to placebo (NNH=143) 5. Enoxaparin is preferred over UFH when feasible due to superior efficacy in preventing reinfarction, ease of administration, and no need for aPTT monitoring 5, 6, 7.
Duration of Therapy
Continue anticoagulation for the duration of index hospitalization, up to 8 days, or until revascularization is performed 1. This extended duration beyond the traditional 48 hours is supported by the guideline's Class I recommendation and allows for adequate antithrombotic coverage during the vulnerable post-MI period.